Pipeline

Medicines in Development

Tasly U.S., “Dedicated to a Healthier World,” has a range of alternative medicines in development that are intended to address unmet health needs and offer disease prevention options in a number of key medical areas, including cardiovascular health, liver health, oncology, immunology and stem cell research.

Areas	Program	Classification	Indication	Development Stage					Status
				PRE-CLINICAL	PHASE I	PHASE II	PHASE III a	PHASE III b
Cardiovascular	T89	Herbal	Chronic stable angina						Phase III trial completed
Cardiovascular	T89	Herbal	Chronic stable angina						Phase III ORESA study ongoing
Cardiovascular	T89	Herbal	Acute mountain sickness (AMS)						Phase II T89-30-AMS trial completed; Phase III clinical trial will be initiated in Q2 of 2021
Oncology	TSL1502	Small Molecule	Ovarian cancer, prostate cancer, breast cancer, stomach cancer, and lung cancer, pancreatic cancer						IND granted by FDA in April 2019; Phase I study ongoing (in China)
Liver	HEPA44	Polypeptide	Hepatitis B						Applying for an IND to conduct clinical trial in the U.S.
Stem cell	UMSC01	Stem Cell	Acute myocardial infarction and ischemic stroke						A Phase I open label clinical trial is currently being performed with an estimated completion in 2021.
Immunology	TA06	Biological	An innovative technology of enzymatic digestion, or sample deglycosylation, which significantly boosts anti-PD-L1 antibody binding affinity and signal intensity causing a more precise PD-L1 quantification and prediction of clinical outcome.